Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Synthetic Human Secretin in Acute Pancreatitis
NCT03686618Phase 2Unknown
- Sponsor
- ChiRhoClin, Inc.
- Start
- Oct 2018
- Primary completion
- Oct 2019
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of secretin in acute pancreatitis (AP) (4 cohorts), sponsored by ChiRhoClin, Inc. Primary endpoint: Decrease in serum C-reactive protein level by 50%. Status: unknown.
02
Drugs
secretin
03
Conditions
acute pancreatitis (AP)
Beyond the preview
Go deeper on NCT03686618.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03686618.